Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...

Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according ...

Most people have missed a dose of prescription medication at some point. But if you are taking a glucagon-like peptide-1 drug ...

McDonald's shares underperformed in 2024, likely due to the rise of GLP-1 medications. Learn why MCD stock is a Sell.

The following is a summary of “Treatment of Hypothalamic Obesity With GLP-1 Analogs,” published in the November 2024 issue of Endocrinology by Dimitri and Roth. Damage to hypothalamic nuclei or ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

Data from Hengrui’s Phase II trial for its GLP-1/GIP product demonstrated a statistically significant mean weight loss of ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...

Designed to transform the treatment landscape for diabetes, metabolic syndrome and weight loss, Laxxon's breakthrough oral GLP-1 agonist, LXM.2, offers a once-daily robust alternative to injections ...

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

Dr. Mehmet Furkan Burak said people who have lost weight and then gained it again can feel guilt or shame and blame ...